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Heat shock proteins 60 (HSP60) is one of the most well studied member of the HSP family.
Although found to be a target self antigen in pathological autoimmunity and HSP60-reactive
T and B cells are part of immune responses in several infectious diseases, there is consis-
tent experimental evidence that HSP60 displays dominant immunoregulatory properties.
There are a series of reports on animal models showing that the administration of HSP60
can modulate inﬂammatory diseases. However, HSP60 has both immune-regulatory and
inﬂammatory properties placing it as an essentially homeostatic antigen, but with poten-
tially harmful effects as well. There have been a series of reports on the successful use of
HSP60 and its peptides as immune-modulatory agent for several models of autoimmune
diseases and in some clinical trials as well. We believe that the potential risks of HSP60
as a therapeutic agent can be controlled by addressing important factors determining its
effects.These factors would be route of administration, appropriate peptides, time point of
administration in the course of the disease, and possible association with other modulatory
agents.
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HSP60 AS AN IMMUNODOMINANT HOMEOSTATIC ANTIGEN
Heat shock proteins (HSP) are highly conserved proteins during
evolution. Besides being upregulated in stress conditions, they are
constitutively and abundantly present in all living beings and are
profoundly involved in various intracellular and systemic home-
ostatic functions in different species (Hemmingsen et al., 1988;
Karlin andBrocchieri,2000). This feature canbe illustratedby their
capacity to prevent protein degradation in salamanders or in trop-
ical trees that live exposed to very high temperatures (Kusukawa
and Yura, 1988), or by their capacity to interact with the immune
system in mammalians, contributing to the ﬁne tuning of inﬂam-
mation (Pockley et al., 2009), and participating in cell survival
signaling pathways (Chun et al., 2010). These robust homeostatic
properties and their marked evolutionary conservation lead us to
think that HSP can be considered as dominant homeostatic mol-
ecules in evolution. Taken the diversity of HSP families (classiﬁed
according to their molecular weight), it is possible that differ-
ent HSP families play differential roles in the complex integrated
homeostatic network.
Heat shock proteins 60 is one of the most well studied HSP,
especially in the interaction with the immune system. It was
ﬁrst described as intracellular chaperone, assisting the folding of
polypeptides intoproteins and the transportingof proteins (Bukau
et al., 2006), but later it was found to be a dominant antigen
recognized during infections, together with HSP70 (Kaufmann,
1990; Zügel and Kaufmann, 1999). These properties place these
two proteins in a special category as antigens. Indeed, HSP60 has
been intensely studied in various immunologic contexts such as
in autoimmune diseases (Danielle et al., 1992; Tanaka et al., 1999;
Dieude et al., 2004; Quintana et al., 2004, 2008; Van Eden et al.,
2005) – often considered as an important target molecule in the
pathogenesis – in tumors (Michaluart et al., 2008; Victora et al.,
2009) and in transplantation (Qian et al., 1995; Birk et al., 1999;
Granja et al., 2004). But, HSP60 does not seem to be a relevant
antigen only in pathological conditions. Autoreactivity to HSP60
is also found in health and a high frequency of B and T cell clones
reactive to self HSP60 is found inphysiological conditions inmam-
malians (Munk et al., 1989; Fischer et al., 1992; Abulaﬁa-Lapid
et al., 1999; Pockley et al., 1999).
Heat shock proteins have been considered by Irun Cohen
(Cohen and Young, 1991) as immunodominant antigens for self
immune responses and as key players in physiological autoimmu-
nity, likely to be involved in homeostasis (Cohen and Lohse, 1991;
Cohen, 1992). In line with this idea, self-HSP-reactive T and B cell
clones can be seen as an important part of a network of regulatory
cells and molecules in the immune system engaged in homeosta-
tic activities (Cohen, 2007). These activities would include tissue
maintenance and repair, but also limiting clonal expansion and
controlling inﬂammation.
Since the discovery of AIRE and its role in the expression of var-
ious tissue speciﬁc antigens by thymic medullary epithelial cells
(MEC; Anderson et al., 2002), it became clear that the different
levels of expression of these antigens placed them at a hierarchi-
cal order of relevance for central tolerance (Kyewski and Klein,
2006). All highly expressed antigens would compose a particular
set of “dominant” antigens relevant for the immune homeostasis
(Coutinho and Haas, 2001). In this sense, HSPs can be consid-
ered as strong candidates to be part of this immunodominant
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homeostatic self. They are ubiquitous antigens expressed both in
housekeeping as well as in stressed circumstances, and they are
highly expressed in the thymus (Mamalaki et al., 1996). Taken that
transgenic expression of HSP60 in the thymus does not lead to
the deletion of HSP60 speciﬁc T cell clones (Minter and Osborne,
2003), it is possible that central tolerance to HSPs relies on the
generation of natural regulatory T cells (nTregs) akin to the way
tolerance is imposed to many other self antigens (Coutinho et al.,
2005; Aschenbrenner et al., 2007). Indeed, nTregs do recognize self
antigens and HSPs, including HSP60, are likely to be among these
self antigens. In addition, HSP60 has a strong effect in the survival
and function of CD4+CD25+Foxp3+ regulatory T cells (Zanin-
Zhorov et al., 2006) and they were shown to efﬁciently drive
the differentiation of CD4+CD25− T cell clones derived from
Juvenile idiopathic arthritis (JIA) patients into CD4+CD25high
regulatory T cells expressing GITR, CTLA-4, and Foxp3 (de Kleer
et al., 2004).
In addition to the reported immunomodulatory effect of
HSP60, it is clear that this molecule also displays inﬂamma-
tory actions. HSP60 activates both innate and adaptive arms of
the immune response being considered as a danger signal that
ampliﬁes inﬂammation and inﬂuence a wide range of immune
reactions (Chen et al., 1999; Wallin et al., 2002; Habich and
Burkat, 2007). Anti-HSP antibodies and HSP60-reactive T cells
are part of immune responses in several infectious diseases (Kauf-
mann, 1990). Approximately 10–20% of the speciﬁc T cells in
mice immunized with Mycobacterium tuberculosis are against the
bacterial HSP65 (Kaufmann et al., 1987). Antibodies to HSP60
of Chlamydia trachomatis have been detected at high levels in
the sera of infected patients (Sanchez-Campillo et al., 1999), and
immunodominant responses to HSP60 are present in other fungal
infections (Matthews et al., 1998). This strong immune response
directed to HSP60 during infection can be explained by its critical
role in cellular homeostasis and by its upregulation in host tissues
as a result of stress during infection. In addition, antibodies as well
as effector pathological T cells reactive to self HSP60 were found
in different autoimmune and inﬂammatory diseases including
type 1 diabetes (Elias et al., 1991; Birk et al., 1996; Abulaﬁa-
Lapid et al., 1999) rheumatoid arthritis (RA), multiple sclerosis
(Quintana et al., 2008), lupus erythematosus (Dieude et al., 2004),
atherosclerosis (Xu et al., 1993), Behcet’s disease (Tanaka et al.,
1999), inﬂammatory bowel disease (Stevens et al., 1992), and
inﬂammatory skin disorders (Bayramgurler et al., 2004).
Although HSP60 was ﬁrst found to be a mitochondrial protein
(McMullin and Hallberg, 1988), it is now known that, in eukary-
otes, it can also locate in the cytosol (Chandra et al., 2007), at the
cell surface (Wand-Wurttenberger et al., 1991; Soltys and Gupta,
1997), in the extracellular space (Davies et al., 2006), and solu-
ble in the peripheral blood (Cappello et al., 2008). In addition,
HSP60 peptides can be also be presented in MHC class I and class
II molecules (Koga et al., 1989; Anderton et al., 1995), activating
speciﬁc CD8+ and CD4+ T cells (Van Eden et al., 2005). Thus,
we believe that many of its immunologic functions may be trig-
gered/modulated by soluble HSP60 and its peptides present in the
microenvironment. In this respect, several synthetic HSP60 pep-
tides have been shown to be immunologically active in vitro (Paul
et al., 2000; Caldas et al., 2004; Van Eden et al., 2005) and in vivo
(Elias and Cohen, 1995; Huurman et al., 2007), but the repertoire
of HSP60 peptides actually generated in vivo in different physio
and pathological contexts is still unknown.
Immunologic activation induced by any type of stimulus trig-
gers a variety of both inﬂammatory and anti-inﬂammatory mech-
anisms, and the capacity to both induce and control inﬂammation
is critical to homeostasis. HSP60 has both properties placing it as
an essentially homeostatic antigen, but with potentially harmful
effects as well. Thus, we think it is crucial to always look at both
functional sides of the immune response in any given immuno-
logic context. We have proposed the term REG/INFLAMMA to
denote functional activities predominantly immunoregulatory or
proinﬂammatory of any given immune molecule. In our descrip-
tive model, a REG/INFLAMMA molecular panel of immunologi-
cally relevant transcription factors (such asGATA-3,RORγt,T-bet,
Foxp3) and cytokines (such as IL-6, TGF-β, IL-10, IFN-γ, TNF-α)
is used as a way to evaluate the overall immunologic activity of a
given molecule or of a particular pathological context (Moraes-
Vieira et al., 2012). We believe this may be a useful strategy to
evaluate the functional activities of HSP60 peptides, for selecting
adequate candidates for clinical application. As a matter of fact,
for the speciﬁc selection of HSP60 peptides, the REG/INFLAMMA
panel could be expanded to also include relevant innate molecules,
since HSP60 and its derived peptides also interact with a variety
of these molecules.
Some of theHSP60-autoreactive T cell clones have been already
isolated frommice (Birk et al., 1996), rats (Feige andCohen, 1991),
and humans (Caldas et al., 2006), under a variety of inﬂamma-
tory conditions, showed REG and INFLAMMA properties in vitro
and in vivo. This dual immunologic activity places Hsp60 and its
derived peptides in a privileged position as potential therapeutic
immunomodulators, to either amplify or control inﬂammation.
On the other hand, the same duality also poses a concern for
clinical application because it is still unclear what determines a
predominant REG or INFLAMMA outcome induced by HSP60
and derived peptides, as previously discussed (Coelho et al., 2008).
HSP60 REGULATORY ACTIVITY IN INFLAMMATORY
DISEASES
Although found to be a target self antigen in pathological autoim-
munity, there is consistent experimental evidence that HSP60 dis-
plays dominant immunoregulatory properties. There are a series
of reports on animal models showing that the administration of
HSP60 can generate T cell responses that modulate inﬂammatory
diseases (arthritis, type 1 diabetes, atherosclerosis, EAE, asthma,
lupus, dermatomyositis; Quintana and Cohen, 2011).
Administration of HSP60 and its peptides by oral, nasal,
intraperitoneal, and subcutaneous routes has been extensively
studied in experimental models of arthritis in rats (Van Eden et al.,
2005). The protective effects of these protocols lead some groups
to explore the reactivity of T cells of patients with JIA and RA to
HSP60. Interestingly,HSP60-reactive T cells isolated from JIA, but
not from AR, patients display a regulatory phenotype and secrete
predominantly cytokines such as IL-10 e TGF-beta (de Kleer et al.,
2004).
Intranasal and oral administration of HSP65 from Mycobac-
terium tuberculosis has been also tested with success in the
Frontiers in Immunology | Inﬂammation January 2012 | Volume 2 | Article 97 | 2
Coelho and Faria HSP as immunoregulatory agent
Ldlr−/− mice which develop atherosclerosis upon feeding a
hypercholesterolemic diet (Harats et al., 2002; Maron et al.,
2002). HSP65-treated mice showed a co-relation between plaque
reduction and IL-10 expression at the aortic arch (Maron et al.,
2002).
In the NOD mice, a type 1 diabetes model, systemic treatment
with HSP65 from Mycobacteria as well as with HSP60 p277 pep-
tide trigger immunoregulatory pathways that result in suppression
of disease (Elias et al., 1991; Elias and Cohen, 1995; Birk et al.,
1996). Phases II and III clinical trials using HSP60 p277 in patients
with type 1diabetes have been successful in the preservationof islet
beta-cell function (Raz et al., 2001, 2007) and, more recently, also
in a randomized phase III trial with over 400 newly diagnosed
type 1 diabetes patients. Other clinical trials employing HSP60
peptides arrested the autoimmune destruction in patients with
RA (van Roon et al., 1997; de Kleer et al., 2004), and autoimmune
uveitis (Stanford et al., 2004).
The capacity of HSP60 to control inﬂammation in the context
of transplantation seems to be a harder task. May be this is related
to the more robust inﬂammatory response, simultaneously trig-
gered by multiple alloantigens, in an already highly inﬂammatory
milieu induced by surgery, in contrast to the more insidious devel-
opment of inﬂammation in autoimmune diseases, together with
the insidious occurrence of epitope spreading to newly exposed
self antigens. Nonetheless, our group has been investing on the
identiﬁcation of potent HSP60 immunoregulatory peptides for
use in allotransplantation. We have been able to prolong allograft
survival across both minor (Luna et al., 2007) and major (unpub-
lished data from V. Coelho laboratory) alloantigen disparities but
so far, we have been unsuccessful in inducing transplantation tol-
erance. Nevertheless, other investigators have been able to induce
transplantation tolerance in a mouse model of skin allograft (Birk
et al., 1999), but publications in this ﬁeld are scarcer. Despite the
difﬁculties, we believe it is worth investing on the use of HSP60
peptides as immunomodulators in allotransplantation;may be not
alone, but in combination with other drugs and immunoregula-
tory molecules. If HSP60 and its peptides are, indeed, endoge-
nous immunoregulators, we should ﬁnd ways to enhance/activate
endogenous immunoregulatory networks, in a synergic manner
with other therapies. This strategy seems particularly relevant
to transplantation, due to the multicity of antigens involved in
triggering inﬂammation; each pair of donor/recipient comprise a
different set of alloantigens inducing aggression against the graft.
If we are able to identify combinations of conserved dominantly
immunoregulatorHSP60peptides, they couldbeused in allotrans-
plantation, alone or in combinationwith other immunoregulatory
therapies, irrespective of speciﬁc alloantigen disparities. A broad
immunoregulatory effect is likely to occur once human HSP60
DNAvaccination has been able to control disease inNODdiabetes,
inducing a Th2-like immune response not only to HSP60 but also
to other relevant target self antigens, such as GAD (glutamic acid
decarboxylase) and insulin (Quintana et al., 2002).
IMMUNOREGULATORY MECHANISMS INDUCED BY HSP60
Heat shock proteins 60 and derived peptides are able to exert an
important role in the ﬁne balance between promoting and control-
ling inﬂammation through a variety of mechanisms. It is very likely
even that HSP60’s REG and INFLAMMA functional activities
occur simultaneously within an inﬂammatorymicroenvironment,
probably also mediated by its different peptides, affecting different
cell types, and mobilizing different molecular pathways. However,
it is not known whether speciﬁc molecular signals, either immune
cell or tissue-derived, inﬂuence HSP60’s functional activity in the
course of inﬂammation. Maybe there is also a time course dif-
ference – a proinﬂammatory predominance at the initial phase of
inﬂammation and a regulatory one at a later time point – aswe pre-
viously suggested in the context of human renal transplantation
(Granja et al., 2004).
Heat shock proteins 60 can be viewed as a protein antigen that
will be processed and presented to T cells inducing a typical lym-
phocyte reaction. However, HSP60 and its various peptides have
the capacity to interact with a variety of immune molecules, intra-
cellularly (Cappello et al., 2008; Chun et al., 2010) and at the
cell surface such as with TLR2, TLR4 (Vabulas et al., 2001), and
MHC molecules (Newcomb and Cresswell, 1993), bridging innate
and adaptive immune responses. Therefore,plasticity andmultiple
connectivity are also striking immunologic properties of HSP60.
An important issue that may be raised regarding this plasticity
is the relationship between the dual role (regulatory and inﬂam-
matory) of HSP60 with its binding molecules. The signaling of
an endogenous protein expressed in low amounts chronically may
lead to distinct patterns of activation of TRL-expressing cells such
as dendritic cells, macrophages, and T cells. In this respect, we
would like to highlight the complex diversity of effects triggered
by different molecules through the same receptor on different
cell types. For instance, it has been shown that both HSP60
and HSP70 signaling, through TLR2 and NF-κB activation, on
murine cardiomyocytes induce, in vitro, contractile dysfunction
and cell death (Mathur et al., 2011). The treatment of human
CD4+CD25+ Tregs with human HSP60 or its p277 peptide
before anti-CD3 activation also enhanced their ability to down-
regulate proliferation and production of IFN-γ and TNF-α by
CD4+CD25− or CD8+ target T cells. In addition, the enhancing
effects of HSP60 costimulation on Tregs involved innate signal-
ing via TLR2, led to activation of PKC, PI3K, and p38, and were
further enhanced by the inhibition of ERK. HSP60-treated Tregs
suppressed target T cells both by cell-to-cell contact and by secre-
tion of TGF-β and IL-10 (Zanin-Zhorov et al., 2006). HSP60 is
also a ligand that activates B cells via TLR4. Simultaneous liga-
tion of TLR4 and BCR in HSP60 speciﬁc B cells induces antibody
secretion (Cohen-Sfady et al., 2005; Herlands et al., 2008) and
this may be an important way to induce the anti-HSP60 IgM
autoantibodies that are prevalent in physiologic conditions (Merbl
et al., 2007). TLR4 ligation in epithelial cells are also known
to play a protective role in the intestinal mucosa. On the other
hand, high concentrations of HSP60 usually trigger TLR4 signal-
ing and inﬂammatory activation of monocytes (Pockley et al.,
2009).
Adding more complexity to the plethoric immunobiology of
HSP60, it was recently reported that HSP60 interacts with beta-
catenin, increasing its transcriptional activity and protein expres-
sion, and favoring metastasis (Tsai et al., 2009). Taken that beta-
catenin also enhances cell survival of several cell types including
Tregs (Ding et al., 2008), it is plausible that this may represent an
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additional pathway bywhichHSP60 andderived peptides promote
immunoregulatory activity.
THERAPEUTIC USE OF HSP60 FOR INFLAMMATORY
DISEASES: ADVANTAGES AND RISKS
Since administration of Hsp60 has a well documented regulatory
effect in inﬂammatory diseasemodels, it has been proposed by sev-
eral groups that this antigen may be used as a therapeutic tool in
diseases where inﬂammation is undesirable such as autoimmune
and allergic diseases and transplantation.
Despite the concerns about the potential risks of inducing
inﬂammatory undesirable effects,different formulations of HSP60
and derived peptides have been used for immunoregulation in a
variety of animal models, and no evidence of pathological autoim-
munity was detected. Accordingly, we have not found histopatho-
logical signs of inﬂammation in over 10 tissues following the use
of the HSP65-DNA vaccine, in mice (Lima et al., 2009). Never-
theless, we believe that the use of HSP60 peptides displaying a
predominant immunoregulatory function, instead of the whole
molecule, may reduce potentially harmful effects. In addition, this
strategymayprovide anopportunity to combine different peptides
which trigger distinct immunoregulatory mechanisms. Nonethe-
less, depending on the route of administration, the quantity of
peptides required may be a limiting issue for clinical application.
Another risk that can be foreseen for the use of HSP60 is a
possibility of immunosuppression to protective responses against
infection. Experiments carried out by our group have shown that
mice treated with HSP65 by the oral route for 4 days have decrease
immune responses to HSP65 but show a normal response to Sal-
monella infection (Rezende et al., unpublished results). The course
of infection was not altered by the treatment suggesting that pro-
tective responses to infectious agents may rely on other potent
pathogen-associated antigens.
On the contrary, in infectious contexts, immune response to
bacterial antigens might beneﬁt from the fact that there is a high
frequency of self-HSP-reactive T and B cell clones in a normal
repertoire. These HSP-reactive lymphocytes would be recruited
and take part in the ongoing immune response, exerting mainly
a regulatory role and contribute to reestablishing homeostasis
(Cohen andYoung, 1991). Indeed, immunomodulation of inﬂam-
matory responses during infection is critical for the outcome of
the infectious disease. There are several examples of infectious
diseases in which severity of disease is mostly related to a high
prevalence of proinﬂammatory cytokines (especially TNF-α) and
poor immune-regulatory components (such as IL-10 or Tregs).
This is true for Chagas disease (Vitelli-Avelar et al., 2008), Schisto-
somiasis (Wamachi et al., 2004), and Leishmaniasis (Oliveira et al.,
2011).
It has been shown that effector CD4+ T cells that
secrete large amounts of IL-2 are able to efﬁciently recruit
CD4+CD25+Foxp3+ regulatory T cells (Curotto de Lafaille et al.,
2004; Almeida et al., 2006). IL-2 is a critical cytokine for Treg
function and this is one of the mechanisms triggered during
inﬂammatory events capable of modulating the degree of tissue
damage without compromising needed inﬂammatory responses.
Therefore, the REG/INFLAMMA balance is an essential part of all
inﬂammatory responses. HSPs ﬁt very well to this picture since
they are self proteins ubiquitously expressed and also they are
upregulated in stress conditions.
The fact that HSP60 is an ubiquitous molecule, on the other
hand,may represent another beneﬁt. Its use would circumvent the
need for the identiﬁcation of the target antigens involved in the
induction of each inﬂammatory disease. In this regard, it has been
demonstrated that tolerance induced to an antigen can recruit
regulatory T cells and molecules that would spread their effect
in a bystander fashion (Miller et al., 1991). This bystander effect
depends on the antigen presenting cells that induce the regulatory
T cells and it recruits for the modulatory immune network most
the antigens presented in the same context.
In view of these potential risks and beneﬁts, we believe that
some issues have to be addressed on the therapeutic use of HSP60
as an immunoregulatory agent: route of administration, form
of the protein (whole molecule, peptides), time point in the
course of the disease, possible association with other modulatory
agents.
ROUTE OF ADMINISTRATION
The majority of studies on the use of HSPs and HSP60 as modula-
tory agents in several models of inﬂammatory diseases have used
the parenteral (subcutaneous, intraperitoneal, intravenous, and
intramuscular) route of administration (Van Eden et al., 2005),
probably because of its easy translation into a later clinical set-
ting. However, we believe it is time to reexamine the pros and
contras of the routes in the light of new knowledge on HSP60
immunobiology.
It has been extensively described that the oral route is a very efﬁ-
cient way to induce peripheral tolerance in animal models (Faria
andWeiner, 2006) and also in humans (Mestecky et al., 1996). Oral
tolerance is a well known phenomenon that probably accounts for
the robust balance that keeps the homeostasis of the gut mucosa to
the daily challenge of microbiota and dietary antigens (Faria and
Weiner, 2005). Indeed, we are all tolerant to the food proteins we
ingest and also to our microbiota and this has been documented in
mice and humans (Andrade et al., 2006; Round et al., 2010). This
is especially interesting regarding HSP because bacterial compo-
nents of our microbiota do express HSPs and they are likely to
be involved in immunoregulatory networks in the gut. Although
many of these proteins are intracellular, we now know that HSP60
can also be expressed at the cell surface and in the extra cellu-
lar space, therefore providing a variety of molecular forms and
pathways by which HSP60 could affect the immunologic milieu
in the gut. In addition, it is plausible that some of the luminal
contents (including dead bacteria) in contact with the abundant
lymphoid tissue of the gut mucosa would induce regulatory T cells
and oral tolerance. Therefore, oral tolerance to our microbiota can
be envisaged as a peripheral form of homeostasis reinforcement
of tolerance involving HSPs.
Of all the feeding regimens already tested for oral tolerance,
continuous feeding has been shown to be the most efﬁcient way
to induce tolerance. Continuous feeding of antigen, but not gav-
age, can render otherwise refractory animals, such as aged mice,
tolerant. Moreover, oral tolerance induced by continuous feeding
of antigen lasts longer and, in mice, do not require any type of
reinforcement during their lifetime (Faria et al., 1998, 2003).
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Since continuous feeding protocols are very cumbersome for
human studies, the use of a probiotic vehicle has been designed
to continuously deliver Mycobacterium leprae HSP65 in the gut
mucosa upon a single administration daily. This strategy associates
the immunomodulatory and tolerogenic potential of HSP65 and
of the gutmucosa.Weobserved that oral administration of Hsp65-
producingLactococcus lactis preventedEAE inmice (Rezende et al.,
unpublished results). Histological analysis showed no inﬂamma-
tory cell inﬁltrate and no tissue destruction in the spinal cord
of HSP65-treated mice. Moreover, increased frequency of regu-
latory T cells correlated with the treatment. Thus, this strategy
may constitute a promising alternative therapy for the treatment
of autoimmune and inﬂammatory diseases.
Nasal administration of antigens is also an effective form of
inducing long living tolerance (Mestecky et al., 1996; Faria and
Weiner, 2006). Regulatory elements triggered by nasal versus oral
administration of antigen may be distinct but both routes have
been described as efﬁcient ways to modulate inﬂammatory dis-
eases by HSP60, including reducing atherosclerotic plaque forma-
tion in the Ldlr−/− mice (Maron et al., 2002) and prolonging
allograft survival in mice (Luna et al., 2007). We would like to
point that other forms of continuous delivery of HSP60 have been
explored with success. Accordingly, intranasal administration of
HSP60 peptide p277 encapsulated into polylactide-co-glycolide
acid microspheres resulted in increased skin graft survival in two
combinations of murine strains with minor H-2 disparities (Luna
et al., 2007).
We believe that the use of strategies such as continuous deliv-
ery of antigen by mucosal routes is an appropriate way to favor
anti-inﬂammatory activities of HSPs by mimicking natural routes
of tolerance induction and should be further explored.
WHOLE PROTEIN OR PEPTIDES?
An important caveat regarding the in vitro functional studies using
recombinant HSP60 is endotoxin contamination which, even at
very low concentrations, may still inﬂuence cytokine produc-
tion and immune cell functional activity. This seems particularly
important because HSP60 and its derived peptides bind to TLRs,
including TLR4which is also a ligand to endotoxin, raising contro-
versies regarding HSP60 speciﬁc immunologic effects. This issue
has been extensively discussed in the literature and several inves-
tigators claim that there is sufﬁcient evidence to support HSP60
speciﬁc signaling actions (Henderson et al., 2010). Indeed,working
with low-endotoxin HSP60 recombinant preparations has mini-
mized the effect of bacterial contaminants. However, we believe
this issue will only be clearly solved when HSP60 produced in
endotoxin-free systems is used for functional assays. Taking this
into consideration, aswell asHSP60REG/INFLAMMAproperties,
several groups and ours have been exploring the immunologic
functions of HSP60 synthetic peptides in a variety of patholog-
ical and physiological (Prakken et al., 1997; Luna et al., 2007)
contexts, and have identiﬁed immunologically active peptides,
effective in, at least partially, downregulating inﬂammation in ani-
mal models (Elias et al., 1991; Thompson et al., 1998; Luna et al.,
2007) and in humans in the context of diabetes (Raz et al., 2001,
2007).
Using a panel of HSP60 synthetic peptides and a gene panel
of predominantly REG/INFLAMMA molecules, we have found
several peptides displaying the capacity to simultaneously modify
the gene expression of a variety of immune molecules, in vitro, and
have identiﬁed somepredominantlyREGandothers INFLAMMA,
using both mouse splenocytes and human peripheral blood
mononuclear cells (PBMC; unpublished data from V. Coelho’s
laboratory). Interestingly, some predominantly regulatory HSP60
peptides were shared by the two species, suggesting evolutionary
functional conservation.
TIME POINT OF THE DISEASE
For oral administration protocols, it is well established that the reg-
ulatory mechanisms of oral tolerance is very efﬁciently triggered
before inﬂammation onset and their efﬁciency declines progres-
sively after sensitization. Therefore, for oral administration of
hsp65, early diagnosis and treatment would be the ideal protocol.
This will be critical for HSP60 administration considering the dual
functional properties of the antigen (REG–INFLAMMA).Another
way to circumvent this caveat of oral treatment with HSP60 might
be the association with a delivery system that could act as a
modulatory adjuvant boosting the tolerogenic effect of HSP60.
As mentioned before, it is not known whether speciﬁc molec-
ular signals from the tissues inﬂuence HSP60’s functional activity
in the course of inﬂammation. It is possible that a time course
difference exists as we have observed in patients who had renal
transplants (Granja et al.,2004).Autoreactivity toHSP60displayed
a proinﬂammatory effect at the initial phase of transplantation and
a regulatory one at a later time point.
ASSOCIATION WITH OTHER MODULATORY AGENTS
Since immune tolerance mediated by HSP60 could be more dif-
ﬁcult to induce in sensitized diseased individuals, the use of
modulatory adjuvants might be helpful. If the oral route is cho-
sen, probiotic bacteria would be excellent candidates since they
are well known as agents with immunomodulatory properties.
Several probiotic bacteria are already inuse for this purpose (Lacto-
bacillus,Biﬁdobacteria, Lactococcus) and the ones that were geneti-
cally engineered to express immune-relevant proteins are specially
interesting (Pontes et al., 2011). A trial on IL-10-producing L.
lactis is currently been carried out after promising results in ani-
mals models of inﬂammatory bowel disease (Braat et al., 2006).
Hsp65-producing L. lactis would also fulﬁll these requirements
since the bacteria L. lactis has modulatory properties on its own
(unpublished data) besides their effect as delivery agent.
Another interesting strategy recently reported is the use of
a pathologically relevant antigen along with HSP60 to induce
immunomodulation. Nemirovsky and coworkers used amyloid
beta peptide Aβ1–15 conjugated with HSP60 peptide p458 in
a subcutaneous vaccination protocol for a murine experimen-
tal model of Alzheimer disease. The combined peptide vaccine
resulted in a signiﬁcant decrease in cerebral amyloid burden and
inﬂammation in the brain (Nemirovsky et al., 2011). A similar
approach could be designed for autoimmune diseases such as type
1 diabetes, arthritis, myasthenia gravis, and others for which a
target self molecule has already been identiﬁed.
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CONCLUDING REMARKS
The dual immunologic role of HSP60 and derived peptides –
inﬂammatory and regulatory – can be viewed as an advan-
tage for multiple clinical applications, either boosting effector
responses or controlling inﬂammation. On the other hand, it also
raises concerns, since it is still unclear what determines HSP60’s
immune-regulatory or inﬂammatory activities. We believe that
critical factors such as route of administration, time course of
the disease in which it will be used, dosage, HSP60 peptides
chosen, and the combination with other modulatory molecules
may circumvent the putative risks posed by its inﬂammatory
potential.
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